Abstract：
UNASSIGNED: To explore the changes in the coagulation function of patients newly diagnosed with multiple myeloma (MM) at different stages and with different M protein types, and to analyze the correlation between coagulation indexes and β2-microglobulin (β2-MG).
UNASSIGNED: A total of 371 Patients with newly diagnosed MM (n = 371) and healthy controls (n = 48) were selected from January 2016 to December 2022. Baseline data, β2-MG and coagulation index values were collected. Indexes included prothrombin time (PT), activated partial thromboplastin time (APPT), fibrinogen (FIB), thrombin time (TT), fibrinogen degradation products (FDP), and D-dimer(D-D). Patients were divided into different groups according to the Durie-Salmon staging system (DS), the International Staging System (ISS) and disease classification (M protein type). The levels of these six indexes were compared among the groups and the correlation between each index and β2-MG was analyzed.
UNASSIGNED: Compared to the normal control group, the levels of PT, FIB, TT, FDP and D-D in the MM group were significantly higher (all P < 0.001). As DS and ISS staging increased, the levels of PT, TT, FDP and D-D also increased significantly (all P < 0.001). β2-MG was positively correlated with PT, TT, and FDP levels (Spearman r = 0.157, 0.270, 0.108, respectively; all P < 0.05), and negatively correlated with FIB (r = -0.220, P < 0.001). Significant differences existed in the levels of these six indexes among different M protein types (all P < 0.001). Among them, PT and APTT increased significantly in the IgA-κ group, FIB increased in the λ light chain group, TT increased in the IgG-κ group, FDP increased in the κ light chain group, and D-D increased in the IgG-λ group.
UNASSIGNED: The degree of coagulation dysfunction in MM patients increases with disease stage and abnormal increases of various coagulation indicators occur in different M protein types and are closely related to β2-MG.
UNASSIGNED: A total of 371 Patients with newly diagnosed MM (n = 371) and healthy controls (n = 48) were selected from January 2016 to December 2022. Baseline data, β2-MG and coagulation index values were collected. Indexes included prothrombin time (PT), activated partial thromboplastin time (APPT), fibrinogen (FIB), thrombin time (TT), fibrinogen degradation products (FDP), and D-dimer(D-D). Patients were divided into different groups according to the Durie-Salmon staging system (DS), the International Staging System (ISS) and disease classification (M protein type). The levels of these six indexes were compared among the groups and the correlation between each index and β2-MG was analyzed.
UNASSIGNED: Compared to the normal control group, the levels of PT, FIB, TT, FDP and D-D in the MM group were significantly higher (all P < 0.001). As DS and ISS staging increased, the levels of PT, TT, FDP and D-D also increased significantly (all P < 0.001). β2-MG was positively correlated with PT, TT, and FDP levels (Spearman r = 0.157, 0.270, 0.108, respectively; all P < 0.05), and negatively correlated with FIB (r = -0.220, P < 0.001). Significant differences existed in the levels of these six indexes among different M protein types (all P < 0.001). Among them, PT and APTT increased significantly in the IgA-κ group, FIB increased in the λ light chain group, TT increased in the IgG-κ group, FDP increased in the κ light chain group, and D-D increased in the IgG-λ group.
UNASSIGNED: The degree of coagulation dysfunction in MM patients increases with disease stage and abnormal increases of various coagulation indicators occur in different M protein types and are closely related to β2-MG.
摘要：
■探讨新诊断的多发性骨髓瘤（MM）患者在不同阶段和不同M蛋白类型时凝血功能的变化，并分析凝血指标与β2-微球蛋白(β2-MG)的相关性。
■从2016年1月至2022年12月共选择371例新诊断的MM患者（n=371）和健康对照（n=48）。基线数据,收集β2-MG和凝血指数值。指标包括凝血酶原时间（PT），活化部分凝血活酶时间（APPT），纤维蛋白原（FIB），凝血酶时间（TT），纤维蛋白原降解产物（FDP），和D-二聚体(D-D)。根据Durie-Salmon分期系统（DS）将患者分为不同的组，国际分期系统(ISS)和疾病分类(M蛋白类型)。比较各组间6项指标水平,分析各指标与β2-MG的相关性。
■与正常对照组相比，PT的水平，FIB,TT,MM组FDP和D-D显著增高(均P<0.001)。随着DS和ISS分期的增加，PT的水平，TT,FDP和D-D也显著增加(均P<0.001)。β2-MG与PT呈正相关,TT,和FDP水平（Spearmanr分别为0.157、0.270、0.108；所有P<0.05），与FIB呈负相关(r=-0.220,P<0.001)。6项指标在不同M蛋白类型间存在显著差异(均P<0.001)。其中,IgA-κ组PT和APTT明显升高,FIB在λ轻链基团中增加，IgG-κ组TT升高,FDP在κ轻链基团中增加，IgG-λ组的D-D增加。
■MM患者的凝血功能障碍程度随疾病分期而加重，各种凝血指标的异常升高发生在不同的M蛋白类型中，与β2-MG密切相关。
■从2016年1月至2022年12月共选择371例新诊断的MM患者（n=371）和健康对照（n=48）。基线数据,收集β2-MG和凝血指数值。指标包括凝血酶原时间（PT），活化部分凝血活酶时间（APPT），纤维蛋白原（FIB），凝血酶时间（TT），纤维蛋白原降解产物（FDP），和D-二聚体(D-D)。根据Durie-Salmon分期系统（DS）将患者分为不同的组，国际分期系统(ISS)和疾病分类(M蛋白类型)。比较各组间6项指标水平,分析各指标与β2-MG的相关性。
■与正常对照组相比，PT的水平，FIB,TT,MM组FDP和D-D显著增高(均P<0.001)。随着DS和ISS分期的增加，PT的水平，TT,FDP和D-D也显著增加(均P<0.001)。β2-MG与PT呈正相关,TT,和FDP水平（Spearmanr分别为0.157、0.270、0.108；所有P<0.05），与FIB呈负相关(r=-0.220,P<0.001)。6项指标在不同M蛋白类型间存在显著差异(均P<0.001)。其中,IgA-κ组PT和APTT明显升高,FIB在λ轻链基团中增加，IgG-κ组TT升高,FDP在κ轻链基团中增加，IgG-λ组的D-D增加。
■MM患者的凝血功能障碍程度随疾病分期而加重，各种凝血指标的异常升高发生在不同的M蛋白类型中，与β2-MG密切相关。
